HPV World - IARC Handbook on cervical cancer screening: value of this evidence synthesis for modeling
15.02.2023
The International Agency for Research in Cancer (IARC) Handbook on cervical cancer screening (Volume 18, 457 pages) presents and summarizes published evidence on screening methods and practice through narrative and systematic reviews as well as quality assessments.
Visit websiteHPV World - Planning for cervical cancer elimination: The role of simulation modeling
16.01.2023
Following the WHO Director-General’s global call for action towards the elimination of cervical cancer as a public health problem, there were fundamental questions asking what elimination definition and threshold should be used, what prevention strategies could lead to elimination, when elimination could be reached, how many cervical cancers and deaths could be averted on the path to elimination, and what strategies to reach elimination were the most efficient and cost-effective.
Visit websiteHPV World - How does COVID-19 impact cervical screening?
14.01.2023
Even though few countries formally paused cervical screening services or programs during the COVID-19 pandemic, screening visits were reduced in many countries. This reflects a wide range of factors, including limited capacity to offer screening (clinically or in laboratories) and constraints on women being able to attend. These factors could in turn be due to staff shortages, competing work, illness, limited resources or consumables, lockdowns, anxiety about being exposed to COVID-19, or lower saliency of preventive healthcare, among others.
Visit websiteHPV World: HPV vaccine uptake among gay, bisexual, and other men who have sex with men in major Canadian cities
13.12.2022
Men who identify as gay or bisexual or otherwise have sex with men (GBM) are at increased risk for anal cancer and other diseases caused by human papillomavirus (HPV). Rates of anal cancer are 10 to 20 times higher in GBM compared to the general population and can be up to 80 times higher among GBM living with HIV. This population also receives little to no herd immunity from female-only vaccination programs. Thus, they are considered a priority population for HPV vaccination.
Visit websiteCervical cancer elimination in Italy: Current scenario and future endeavors for a value based prevention
13.10.2022
Cervical Cancer (CC) is a vaccine-preventable disease, and it is treatable if diagnosed early and managed properly. However, it is the fourth most common cancer in women worldwide with about 604,127 cases and 341,831 deaths in 2020. In Italy, it represents the fifth most common cancer in women under 50 years of age with about 2,400 new cases in 2020. The CC elimination is today a global public health goal published by the World Health Organization (WHO) in 2020 and a commitment of the European Union that has included it in Europe's Beating Cancer Plan. Therefore, urgent action is needed, at international and national level, to implement value-based interventions regarding vaccination, screening and timely management of the disease. Our study aims to describe the state of the art of Human Papilloma Virus (HPV) prevention in Italy and to get a consensus on indicators for monitoring the progress toward CC elimination at national level.
Visit websiteHPV World: Addressing disparities in HPV vaccination among culturally diverse populations- a socioecological approach
13.10.2022
Infection with Human Papillomavirus (HPV) is the leading risk factor for the development of ano-genital cancers and a major health problem globally. Elimination of HPV morbidities requires four key pillars: prevention, screening, treatment and education. With prevention, global studies have shown that unique socio-cultural norms and environmental factors provide challenges for community acceptance of adolescent HPV vaccination. Furthermore, the empirical evidence highlights that implementation strategies for HPV vaccination programs cannot be generalised to culturally diverse populations.
Visit websitePutting HPV on the Map: The State of HPV Prevention Programmes in the WHO European Region
27.04.2022
There is plenty of work to do to achieve the elimination of all cancers caused by HPV as a public health problem. But, armed with the vital information contained in this report, we will now do what we can to accelerate action at the regional level and also to support advocacy efforts by HPV organisations within individual countries to help ensure that all health systems take the action that is needed to protect their populations effectively. If all countries in the region emulated the current best-performers, almost 100,000 cancer cases a year could be prevented. That would be a remarkable achievement and a world-leading example for other regions to follow.
Visit websiteImproving HPV Vaccine Uptake in Children, Adolescents, and Young Adults: An Umbrella Review of Interventions
25.04.2022
HPV causes about 5% of all cancers worldwide. The most common of these cancers is cervical but the virus is also implicated in cancers of the vagina, vulva, anus, penis, head and neck. A significant proportion of the cancers caused by HPV in Europe are in men. Compared to many other cancer prevention strategies – such as tobacco control, reducing alcohol consumption, increasing physical activity or tackling obesity – HPV vaccination is easy to deliver, has an immediate positive health impact and is highly efficacious. In fact, it is probably the single most effective means of cancer prevention in the medical arsenal. We therefore encourage HPV vaccination programmes in Europe and beyond to make the best possible use of this evidence. If we can achieve a 90% vaccination rate across Europe, we know we will succeed in eliminating HPV cancers as a public health problem in the region.
Visit websiteHPV Vaccination in Women Treated for Cervical Intraepithelial Neoplasia: A Budget Impact Analysis
13.07.2021
Human Papillomavirus (HPV) is the most common sexually transmitted infection. Its progression is related to the development of malignant lesions, particularly cervical intraepithelial neoplasias (CINs). CINs correlate with a higher risk of premature births, and their excisional and ablative treatment further increases this risk in pregnant women. These complications are also correlated with higher healthcare costs for their management. In Italy, more than 26,000 new cases of CINs are estimated to occur yearly and their economic burden is significant. Therefore, the management of these conditions is a public health priority. Since HPV vaccination is associated with a reduced risk of relapse in women surgically treated for HPV-related injuries, we estimated the economic impact of extending HPV vaccination to this target population. This strategy would result in a significant reduction in the general costs of managing these women, resulting in an overall saving for the Italian Health Service of €155,596.38 in 5 years. This lower cost is due not only to the reduced incidence of CINs following vaccination, but also to the lower occurrence of preterm births. Extending HPV vaccination to this target population as part of a care path to be offered to women treated for HPV injuries is therefore desirable.
Visit website